Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture

finance.yahoo.com · 2026-09-15

Analysts think Alnylam could rebound strongly over the next 12 months.

TickrTrends take: The headline describes weakness in Alnylam Pharmaceuticals, a company outside SPGI's Financial Services sector, which may reflect broader market concerns about growth stock valuations and risk appetite. TickrTrends' undervalued assessment of SPGI suggests the market may be applying pessimistic sentiment across sectors indiscriminately, potentially creating opportunities in defensive financial service businesses that maintain stable cash flows. Valuation-focused readers should monitor whether sell-offs in growth-oriented sectors persist, as sustained pressure could either validate SPGI's undervaluation or signal deeper concerns affecting risk assets across the market.

Read the full story at finance.yahoo.com →